A top 10 biopharmaceutical company was looking to gain agility and confidence in their trial planning, site selection, and clinical trial enrollment decisions in a priority indication.

Currently, 80% of trials do not enroll within target enrollment timeframes and 55% of terminated trials cite low patient accrual as the main reason. In such a cut-throat environment, it was critical for this top sponsor to choose high-performing sites based on reliable data to set their trials up for success.

Download this case study to see how Intelligent Trials helped this company:

• Integrate cross-industry clinical trial data with their existing data
• Gain a more robust view of site performance, especially at sites with little data from other sources
• Double the number of high-performing sites identified in their priority indication